1. Home
  2. NCNO vs MIRM Comparison

NCNO vs MIRM Comparison

Compare NCNO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nCino Inc.

NCNO

nCino Inc.

HOLD

Current Price

$23.38

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$68.49

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNO
MIRM
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.7B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
NCNO
MIRM
Price
$23.38
$68.49
Analyst Decision
Buy
Strong Buy
Analyst Count
17
11
Target Price
$33.40
$82.82
AVG Volume (30 Days)
2.2M
549.3K
Earning Date
12-03-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$586,485,000.00
$471,794,000.00
Revenue This Year
$10.88
$53.78
Revenue Next Year
$8.53
$19.91
P/E Ratio
N/A
N/A
Revenue Growth
12.14
53.66
52 Week Low
$18.75
$36.88
52 Week High
$40.29
$78.55

Technical Indicators

Market Signals
Indicator
NCNO
MIRM
Relative Strength Index (RSI) 35.75 44.02
Support Level $24.12 $68.60
Resistance Level $27.50 $71.98
Average True Range (ATR) 0.98 2.55
MACD -0.03 -0.09
Stochastic Oscillator 0.93 7.55

Price Performance

Historical Comparison
NCNO
MIRM

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: